Peptide drug discovery and development: translational research in academia and industry
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
Weinheim
Wiley-VCH
2011
|
| Schlagworte: | |
| Online-Zugang: | Inhaltstext Inhaltsverzeichnis |
| Beschreibung: | XIX, 370 S. Ill., graph. Darst. 240 mm x 170 mm |
| ISBN: | 9783527328918 3527328912 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV039109264 | ||
| 003 | DE-604 | ||
| 005 | 20120726 | ||
| 007 | t | ||
| 008 | 110630s2011 ad|| |||| 00||| eng d | ||
| 015 | |a 11,N17 |2 dnb | ||
| 016 | 7 | |a 1011200457 |2 DE-101 | |
| 020 | |a 9783527328918 |c Gb. : ca. EUR 149.00 (DE) (freier Pr.) |9 978-3-527-32891-8 | ||
| 020 | |a 3527328912 |c Gb. : ca. EUR 149.00 (DE) (freier Pr.) |9 3-527-32891-2 | ||
| 024 | 3 | |a 9783527328918 | |
| 028 | 5 | 2 | |a Best.-Nr.: 1132891 000 |
| 035 | |a (OCoLC)765929312 | ||
| 035 | |a (DE-599)DNB1011200457 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-91G |a DE-526 |a DE-355 |a DE-19 |a DE-M49 | ||
| 082 | 0 | |a 615.10724 |2 22/ger | |
| 084 | |a VS 5350 |0 (DE-625)147687:253 |2 rvk | ||
| 084 | |a CHE 820f |2 stub | ||
| 084 | |a CHE 893f |2 stub | ||
| 084 | |a 610 |2 sdnb | ||
| 100 | 1 | |a Castanho, Miguel |e Verfasser |0 (DE-588)1011408384 |4 aut | |
| 245 | 1 | 0 | |a Peptide drug discovery and development |b translational research in academia and industry |c ed. by Miguel Castanho ... |
| 264 | 1 | |a Weinheim |b Wiley-VCH |c 2011 | |
| 300 | |a XIX, 370 S. |b Ill., graph. Darst. |c 240 mm x 170 mm | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 650 | 0 | 7 | |a Wirkstofffreisetzung |0 (DE-588)4190018-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Peptide |0 (DE-588)4045125-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Arzneimittelforschung |0 (DE-588)4003120-2 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Peptide |0 (DE-588)4045125-2 |D s |
| 689 | 0 | 1 | |a Wirkstofffreisetzung |0 (DE-588)4190018-2 |D s |
| 689 | 0 | 2 | |a Arzneimittelforschung |0 (DE-588)4003120-2 |D s |
| 689 | 0 | |5 DE-604 | |
| 856 | 4 | 2 | |m X:MVB |q text/html |u http://deposit.dnb.de/cgi-bin/dokserv?id=3718083&prov=M&dok_var=1&dok_ext=htm |3 Inhaltstext |
| 856 | 4 | 2 | |m DNB Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=022653020&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-022653020 | |
Datensatz im Suchindex
| _version_ | 1805096280862490624 |
|---|---|
| adam_text |
IMAGE 1
CONTENTS
PREFACE XIII LIST OF CONTRIBUTORS XV
PART I THE ACADEMIA - MARKET BOUNCING OF PEPTIDE DRUGS - CHALLENGES AND
STRATEGIES IN TRANSLATIONAL RESEARCH WITH PEPTIDE DRUGS 1
1 PEPTIDES AS LEADS FOR DRUG DISCOVERY 3
PAULJ. EDWARDS, AND STEVEN R. LAPLANTE 1.1 INTRODUCTION 3
1.2 OVERVIEW OF PROCESS FOR TRANSFORMING PEPTIDES TO PEPTIDOMIMETICS 5
1.3 HCMV PROTEASE 7
1.3.1 HCMV PROTEASE: IDENTIFICATION AND CHARACTERIZATION OF ANTIVIRAL
INHIBITORS TARGETING THE SERINE PROTEASE DOMAIN OF THE HUMAN
CYTOMEGALOVIRUS (HCMV PROTEASE) 7 1.3.2 MAPPING ESSENTIAL ELEMENTS OF
THE SUBSTRATE PEPTIDES AND
DETERMINING STRUCTURES OF LIGANDS BOUND TO HCMV 8 1.3.3 IMPROVING
PEPTIDE ACTIVITY TO ALLOW SAR STUDIES 10 1.3.4 ELUCIDATION OF THE
BINDING MODE OF THE OPTIMIZED PEPTIDYL SEGMENT 10
1.3.5 LIGAND ADAPTATIONS UPON BINDING 12 1.3.6 STRATEGIC SUMMARY FOR
HCMV PEPTIDE MIMIC DESIGN PROCESS 14 1.4 HCV PROTEASE 15
1.4.1 HCV PROTEASE AS AN ANTIVIRAL TARGET 15 1.4.2 NS3 SERINE PROTEASE
POSSESSES A CHYMOTRYPSIN-LIKE FOLD 16 1.4.3 DISCOVERY OF THE PEPTIDE
DDIVPC AS AN INHIBITOR OF NS3 PROTEASE 16 1.4.4 "SENSEMAKING" AND
KNOWLEDGE BUILDING: MAPPING OF THE
CRITICAL BINDING RESIDUES OF THE PEPTIDE AND CREATION OF AN
INHIBITOR-PROTEASE MODEL 18
PEPTIDE DRUG DISCOVERY AND DEVELOPMENT: TRANSLATIONAL RESEARCH IN
ACADEMIA AND INDUSTRY, FIRST EDITION. EDITED BY MIGUEL CASTARIHO AND
NUNO C. SANTOS. 2011 WILEY-VCH VERLAG GMBH & CO. KGAA, WEINHEIM.
PUBLISHED 2011 BY WILEY-VCH VERLAG GMBH & CO. KGAA
BIBLIOGRAFISCHE INFORMATIONEN HTTP://D-NB.INFO/1011200457
DIGITALISIERT DURCH
IMAGE 2
VI I CONTENTS
1.4.5 KNOWLEDGE BUILDING: MONITORING LIGAND FLEXIBILITY IN THE
FREE-STATE AND CHANGES UPON BINDING - P3 RIGIDIFICATION 18 1.4.6
N-TERMINAL TRUNCATION AND IMPROVED PI, P2 AND P5 SUBSTITUENTS 22 1.4.7
MACROCYDIZATION: LINKING THE FLEXIBLE PI SIDE-CHAIN TO P3 25
1.4.8 HCV PROTEASE INHIBITOR BI00201335 29 1.5 HERPES SIMPLEX VIRUS 32
1.5.1 HERPES SIMPLEX VIRUS-ENCODED RIBONUCLEOTIDE REDUCTASE INHIBITORS
32 1.6 RENIN 38
1.6.1 ASPARTYL PROTEASE RENIN AS A TARGET 38 1.7 HIV 45
1.7.1 HIV PROTEASE INHIBITORS 45 1.8 CONCLUSIONS 47
2 MARKETING ANTIMICROBIAL PEPTIDES: A CRITICAL ACADEMIC POINT OF VIEW 57
EDUARD BARDAJ'I 2.1 INTRODUCTION 57
2.2 BASIC RESEARCH: ANTIMICROBIAL PEPTIDES 58 2.3 PATENTS 61
2.4 POTENTIAL APPLICATIONS OF AMPS 63 2.5 TECHNOLOGY TRANSFER:
VALORIZATION, LICENSING, OR SPIN-OFF CREATION 64 2.6 SPIN-OFF CREATION:
AN ACADEMIC POINT OF VIEW 66
3 ORAL PEPTIDE DRUG DELIVERY: STRATEGIES TO OVERCOME CHALLENGES 71
HAMMAN, JOSIAS H. AND STEENEKAMP, JAN H. 3.1 INTRODUCTION 71
3.2 CHALLENGES ASSOCIATED WITH ORAL PEPTIDE DELIVERY 72 3.2.1 TRANSPORT
PATHWAYS ACROSS THE INTESTINAL EPITHELIUM 72 3.2.2 UNFAVORABLE
PHYSICOCHEMICAL PROPERTIES OF PEPTIDE DRUGS 73 3.2.2.1 MOLECULAR SIZE,
HYDROPHILICITY, AND PHYSICAL STABILITY 73
3.2.3 PHYSICAL BARRIERS OF THE GASTROINTESTINAL TRACT 73 3.2.3.1
TRANSCELLULAR PATHWAY 73 3.2.3.2 PARACELLULAR PATHWAY 75 3.2.4
BIOCHEMICAL BARRIERS OF THE GASTROINTESTINAL TRACT 75
3.2.4.1 LUMINAL ENZYMES 76 3.2.4.2 BRUSH BORDER MEMBRANE BOUND ENZYMES
AND INTRACELLULAR ENZYMES 76 3.2.5 EFFLUX TRANSPORT SYSTEMS 76 3.2.6
GASTROINTESTINAL TRANSIT TIME AND SITE-SPECIFIC ABSORPTION 77
IMAGE 3
CONTENTS VII
3.3 STRATEGIES TO OVERCOME THE BARRIERS OF THE GASTROINTESTINAL
TRACT 77
3.3.1 ABSORPTION ENHANCING AGENTS 77 3.3.2 CHEMICAL AND PHYSICAL
MODIFICATIONS 78 3.3.3 TARGETING STRATEGIES 81 3.3.3.1 TARGETING
SPECIFIC REGIONS OF THE GASTROINTESTINAL TRACT 81 3.3.3.2 TARGETING
RECEPTORS AND TRANSPORTERS 82 3.3.4 FORMULATION STRATEGIES 83 3.3.4.1
PARTICULATE CARRIER SYSTEMS 83 3.3.4.2 ENZYME INHIBITION 84 3.3.4.3
MUCOADHESIVE SYSTEMS 84 3.4 CONCLUSIONS 84
4 RATIONAL DESIGN OF AMPHIPATHIC A-HELICAL AND CYCLIC SS-SHEET
ANTIMICROBIAL PEPTIDES: SPECIFICITY AND THERAPEUTIC POTENTIAL 91 WENDY
J. HARTSOCK AND ROBERT S. HODGES 4.1 INTRODUCTION TO ANTIMICROBIAL
PEPTIDES 91 4.2 ANTIMICROBIAL AND HEMOLYTIC ACTIVITIES OF AMPHIPATHIC
A-HELICAL ANTIMICROBIAL PEPTIDES: MECHANISMS AND SELECTIVITY 92 4.3
STRUCTURE-ACTIVITY RELATIONSHIP STUDIES OF AMPHIPATHIC A-HELICAL AND
CYCLIC SS-SHEET ANTIMICROBIAL PEPTIDES: OPTIMIZATION
OF PATHOGEN SELECTIVITY AND PREVENTION OF HOST TOXICITY 94 4.4
COMMERCIALIZATION OF ANTIMICROBIAL PEPTIDES 112 4.5 THERAPEUTIC
POTENTIAL 113
5 CONOTOXIN-BASED LEADS IN DRUG DESIGN 119 MUHARREM AKCAN AND DAVID J.
CRAIK 5.1 INTRODUCTION 119
5.1.1 CONE SNAILS 119
5.1.2 CONOTOXIN DISCOVERY AND CHARACTERIZATION (MS, CDNA, PEPTIDE
SEQUENCING) 120 5.1.3 CONOTOXIN CLASSIFICATION AND TARGETS 121 5.1.4
POSTTRANSLATIONAL MODIFICATIONS (PTMS) 122 5.1.5 PROSPECTS FOR DRUG
DISCOVERY 124
5.2 CONOTOXIN SYNTHESIS, FOLDING, AND STRUCTURE 124 5.2.1 SYNTHESIS 124
5.2.2 FOLDING 127
5.2.3 STRUCTURE BY NMR AND X-RAY 127 5.3 CONOTOXINS AS DRUG LEADS 128
5.3.1 OVERVIEW OF CONOTOXINS IN DRUG DESIGN 128 5.3.2 CO-CONOTOXINS
(MVIIA, CVID) 129 5.3.3 A-CONOTOXINS (VCL.L) 129
IMAGE 4
VIII CONTENTS
5.3.4 X - C O N O T O X I NS (MRIA) 130
5.3.5 RE-ENGINEERED CONOTOXINS IN DRUG DESIGN 131 5.4 CONCLUSIONS 133
6 PLANT ANTIMICROBIAL PEPTIDES: FROM BASIC STRUCTURES TO APPLIED
RESEARCH 139 SUZANA M. RIBEIRO, SIMONI C. DIAS, AND OCTAVIO L FRANCO
6.1 INTRODUCTION 139
6.2 THE DIVERSITY OF PLANT ANTIMICROBIAL PEPTIDES: FOCUSING ON TISSUE
LOCALIZATION AND PLANT SPECIES DISTRIBUTION 139 6.3 POSSIBLE STRUCTURAL
FOLDS FOUND IN PLANT AMPS TO DATE 140 6.4 NEW BIOTECHNOLOGICAL PRODUCTS
PRODUCED FROM PLANT
PEPTIDES 144
PART II PEPTIDE DRUGS' TRANSLATIONAL TALES - PEPTIDE DRUGS BEFORE,
THROUGH AND AFTER INDUSTRY PIPELINES 157
7 OMIGANAN PENTAHYDROCHLORIDE: A NOVEL, BROAD-SPECTRUM ANTIMICROBIAL
PEPTIDE FOR TOPICAL USE 159 EVELINA RUBINCHIK AND DOMINIQUE DUGOURD 7.1
OMIGANAN: A NOVEL ANTI-INFECTIVE AGENT FOR TOPICAL
INDICATIONS 159
7.2 STRUCTURE AND MECHANISM OF ACTION 160 7.3 SPECTRUM OF ACTIVITY 163
7.4 PREDINICAL EFFICACY STUDIES 163 7.5 PRECLINICAL TOXICOLOGY STUDIES
164 7.6 CLINICAL STUDIES 165
7.7 CONDUSIONS 167
8 TURNING ENDOGENOUS PEPTIDES INTO NEW ANALGESICS: THE EXAMPLE OF KYOTO
RP H IN DERIVATIVES 171 MARTA M.B. RIBEIRO, ISA D. SERRANO, AND SONIA SA
SANTOS 8.1 INTRODUCTION 171
8.2 PEPTIDES AS FUTURE DRUG CANDIDATES 171 8.3 CENTRAL NERVOUS SYSTEM
ANALGESIC PEPTIDES 172 8.4 ENDOGENOUS OPIOID SYSTEM 173 8.5 STRATEGIES
TO DELIVER ANALGESIC PEPTIDES TO THE BRAIN 174 8.6 DEVELOPMENT OF NEW
OPIOID-DERIVED PEPTIDES 375 8.7 KYOTORPHIN - THE POTENTIAL OF AN
ENDOGENOUS DIPEPTIDE 177 8.8 NEW KTP DERIVATIVES 178
8.9 ASSESSING BBB PERMEABILITY WITH PEPTIDE - MEMBRANE PARTITION STUDIES
179
IMAGE 5
CONTENTS \ IX
8.10 KYOTORPHINS: PARTITION TO THE MEMBRANE AND ENHANCED
ANALGESIC ACTIVITY 179 8.11 ACADEMIA AND PHARMACEUTICAL INDUSTRY:
FRIENDS OR FOES? 183
9 THE DEVELOPMENT OF ROMIPLOSTIM - A THERAPEUTIC PEPTIBODY USED TO
STIMULATE PLATELET PRODUCTION 189 GRAHAM MOLINEUX AND PING WEI
9.1 INTRODUCTION 189
9.2 THROMBOPOIETIN AND C-MPL 189 9.3 DISCOVERY AND OPTIMIZATION OF
ROMIPLOSTIM 192 9.4 PHARMACODYNAMICS (PD) AND PHARMACOKINETICS (PK) OF
ROMIPLOSTIM 194
9.5 A BRIEF ITP PRIMER 199
9.5.1 DIAGNOSIS AND TREATMENT 199 9.5.2 THROMBOPOIETIN AND ITP 200 9.6
ROMIPLOSTIM CLINICAL DATA 201 9.7 SAFETY AND OTHER INSIGHTS GAINED FROM
ROMIPLOSTIM DESIGN AND
DEVELOPMENT 203
10 HIV VS. HIV: TURNING HIV-DERIVED PEPTIDES INTO DRUGS 209 HENRI C.
FRANQUELIM, PEDRO M. MATOS, AND A. SALOME VEIGA 10.1 INTRODUCTION 209
10.2 HIV-1 ENVELOPE PROTEIN 209 10.3 HIV ENTRY AND ITS INHIBITION 210
10.4 HIV-1 FUSION INHIBITORS: FROM BENCH TO CLINICAL ADMINISTRATION 211
10.5 NEW STRATEGIES FOR CREATING NEW HIV FUSION INHIBITOR PEPTIDES 215
10.5.1 INCREASING HELICITY AND BINDING TO GP41 216 10.5.2 ISOMERIC
PEPTIDES AND RESISTANCE TO PROTEOLYSIS 219 10.5.3 BACTERIALLY EXPRESSED
PEPTIDES 220 10.5.4 MODIFICATION OF PEPTIDES BY DERIVATIZATION WITH
LIPIDS OR PROTEINS 220 10.6 DRUG-RESISTANCE AND COMBINATION THERAPY 222
10.7 CONDUDING REMARKS 223
11 SIFUVIRTIDE, A NOVEL HIV-1 FUSION INHIBITOR 231 XIAOBIN ZHANG, HAO
WU, AND FENGSHAN WANG 11.1 IDEAL DRUG TARGET HIV-1 GP41 231 11.2
STRUCTURE-BASED DRUG DESIGN OF SIFUVIRTIDE 232 11.3 HIGH POTENCY OF
SIFUVIRTIDE 234
11.4 LIMITED DRUG RESISTANCE 235 11.5 ENHANCEMENT OF THE EFFICIENCY OF
SIFUVIRTIDE BY BIOMEMBRANE SELECTIVITY 236 11.6 PHARMACOKINETICS OF
SIFUVIRTIDE WITH LONG HALF-LIFE 237
IMAGE 6
X I CONTENTS
11.7 STRATIFICATION OF MONOTHERAPY 238
11.8 20 MG SIFUVIRTIDE ONCE DAILY VS. 100 MG T20 TWICE DAILY 239 11.9
CONDUSIONS AND DISCUSSION 240
PART III WHITHER PEPTIDE DRUGS? PEPTIDES SHAPING THE FUTURE OF DRUG
DEVELOPMENT 245
12 ENDOGENOUS PEPTIDES AND THEIR RECEPTORS AS DRUG DISCOVERY TARGETS FOR
THE TREATMENT OF METABOLIC DISEASE 247 MARY ANN PELLEYMOUNTER, YUREN
WANG, AND NING LEE 12.1 CENTRALLY SECRETED NEUROPEPTIDE SYSTEMS 248
12.1.1 CORTICOTROPIN RELEASING FACTOR (CRF) PEPTIDES 248 12.1.2 MELANIN
CONCENTRATING HORMONE (MCH) 249 12.1.3 MELANOCORTINS 250
12.1.4 NEUROPEPTIDE Y (NPY) 252 12.1.5 NEUROMEDIN U (NMU) AND NEUROMEDIN
S (NMS) 254 12.1.6 OPIOIDS 255
12.1.7 QRFP 256
12.2 PERIPHERALLY SECRETED NEUROPEPTIDES 256 12.2.1 AMYLIN 256
12.2.2 BOMBESIN-IIKE PEPTIDES (BOMBESIN AND GASTRIN-RELEASING PEPTIDE)
257 12.2.3 CHOLECYSTOKININ (CCK) 258 12.2.4 GHRELIN 259
12.2.5 GLUCAGON-LIKE PEPTIDE-1 260 12.2.6 LEPTIN 261
12.2.7 OXYNTOMODULIN (OXM) 262 12.2.8 PYY3-36 AND PP 262 12.3 SUMMARY
263
13 TRANSLATION OF MOTILIN AND GHRELIN RECEPTOR AGONISTS INTO DRUGS FOR
GASTROINTESTINAL DISORDERS 269 CARETHJ. SAENGER, JOHN BROAD, AND DAVID H.
AIPERS 13.1 INTRODUCTION 269
13.1.1 SIMILARITIES AND DIFFERENCES BETWEEN MOTILIN AND GHRELIN 269
13.1.2 CLINICAL POTENTIAL OF MOTILIN AND GHRELIN RECEPTOR AGONISTS 270
13.2 MOTILIN AND GHRELIN RECEPTOR AGONISTS UNDER DEVELOPMENT 271 13.3
TRANSLATIONAL VALUE OF PREDINICAL ASSAYS 275 13.3.1 MOTILIN 271
13.3.1.1 ASSAYS RELEVANT TO THE THERAPEUTIC MECHANISM OF ACTION 271
13.3.1.2 ASSAYS RELEVANT TO POSSIBLE NON-GI ACTIVITY 275 13.3.2 GHRELIN
276
13.3.2.1 ASSAYS RELEVANT TO THE THERAPEUTIC MECHANISM OF ACTION 276
IMAGE 7
CONTENTS I XI
13.3.2.2 ASSAYS RELEVANT TO NON-GI ACTIVITY 276
13.4 CLINICAL TRANSLATION: SELECTINGTHE "RIGHT" PATIENT POPULATION 277
13.4.1 CRITICALLY 111 PATIENTS WITH DELAYED GASTRIC EMPTYING 279 13.4.2
PATIENTS WITH GASTROPARESIS 279 13.4.2.1 DIABETIC GASTROPARESIS 281
13.4.2.2 PARKINSON'S DISEASE 281 13.4.2.3 CYDIC NAUSEA AND VOMITING 282
13.4.2.4 MIGRAINE 282 13.4.2.5 FUNCTIONAL DYSPEPSIA (FD) 282 13.4.2.6
GASTROESOPHAGEAL REFLUX DISEASE (GERD) 283 13.4.2.7 ANOREXIA AND
DECREASED APPETITE (GHRELIN AGONISTS ONLY) 284 13.5 CLINICAL DEVELOPMENT
OF MOTILIN AND GHRELIN RECEPTOR
AGONISTS 284
13.6 CONCLUSIONS 285
14 OF MICE AND MEN: TRANSLATIONAL RESEARCH ON AMYLIN AGONISM 295
JONATHAN D. ROTH, CHRISTINE M. MACK, JAMES L TREVASKIS, AND DAVID C.
PARKES 14.1 OVERVIEW OF AMYLIN PHYSIOLOGY 295 14.2 PRAMLINTIDE: AN
AMYLIN AGONIST 296 14.3 AMYLIN AGONISM: TRANSLATIONAL RESEARDI IN
INSULIN-DEPENDENT
DIABETES 297
14.3.1 POST-PRANDIAL HYPERGLUCAGONEMIA AND DIABETES 297 14.3.2 AMYLIN
AGONISM AND GLUCAGON: PRECLINICAL AND CLINICAL STUDIES 297 14.3.3
GASTRIC EMPTYING AND DIABETES 298
14.3.4 AMYLIN AGONISM AND GASTRIC EMPTYING: PREDINICAL AND CLINICAL
STUDIES 298 14.4 AMYLIN AGONISM: TRANSLATIONAL RESEARCH IN OBESITY 299
14.4.1 FOOD INTAKE AND BODY WEIGHT: ROLE OF ENDOGENOUS AMYLIN 299 14.4.2
FOOD INTAKE AND BODY WEIGHT: PRE-DINICAL STUDIES 300 14.4.3 FOOD INTAKE
AND BODY WEIGHT: CLINICAL STUDIES 302 14.4.4 COMBINATION STUDIES 304
14.4.5 AMYLIN AGONISM AND SMALL MOLECULE AGENTS 304
14.4.6 COMBINED AMYLIN AND LEPTIN AGONISM 305 14.4.7 FUTURE AREAS FOR
AMYLIN AGONISM-BASED TRANSLATIONAL RESEARCH 307
15 PEPTIDES AND POLYPEPTIDES AS IMMUNOMODULATORS AND THEIR CONSEQUENTIAL
THERAPEUTIC EFFECT IN MULTIPLE SCLEROSIS AND OTHER AUTOIMMUNE DISEASES
313 RUTH ARNON, MICHAEL SELA, AND RINA AHARON!
15.1 INTRODUCTION 313
IMAGE 8
CONTENTS
15.2 PEPTIDES AS ANTIGENS AND VACCINES 314
15.3 PEPTIDES AS IMMUNOMODULATORS 315 15.4 DEVELOPMENT OF COPOLYMER 1 -
A POLYPEPTIDE IMMUNOMODULATOR DRUG FOR THE TREATMENT OF MULTIPLE
SCLEROSIS 316 15.4.1 CLINICAL STUDIES WITH COP 1 IN MS PATIENTS 317
15.4.2 IMMUNOLOGICAL MECHANISMS INVOLVED IN THE MITIGATION OF DISEASE BY
COP 1 318 15.4.3 IMMUNOMODULATION BY COP 1 IN THE CNS 320 15.4.4
NEUROPROTECTION AND AUGMENTATION OF NEUROTROPIC FACTORS IN THE
BRAIN 321
15.4.5 MYELIN REPAIR AND NEUROGENESIS 323 15.4.6 THE EFFECT OF COP 1 ON
ANOTHER AUTOIMMUNE DISEASE - INFLAMMATORY BOWEL DISEASE 326 15.5
ADDITIONAL IMMUNOMODULATORY PEPTIDES AS DRUG
CANDIDATES 327
15.5.1 PEPTIDE THERAPY FOR TYPE 1 DIABETES 327 15.5.2 MYASTHENIA GRAVIS
(MG) 328 15.5.3 A NOVEL TOLEROGENIC PEPTIDE FOR THE SPECIFIC TREATMENT
OF SYSTEMIC LUPUS ERYTHEMATOSUS 328 15.6 SUMMARY AND CONDUDING REMARKS
329
16 DEVELOPMENT OF ANTIBODY FRAGMENTS FOR THERAPEUTIC APPLICATIONS 337
SOFA CORTE-REAL, FREDERICO AIRES DA SILVA, ANDJODO CONCOIVES 16.1
ANTIBODIES 337
16.1.1 ANTIBODY STRUCTURE 338 16.1.2 ANTIBODY FRAGMENTS 341 16.1.3
SINGLE-DOMAIN ANTIBODIES 343 16.1.4 ENGINEERING MULTIVALENT, BISPECIFIC,
AND BIFUNCTIONAL
FRAGMENTS 345
16.1.5 INTRACELLULAR ANTIBODIES (INTRABODIES) 347 16.1.5.1
IMMUNOGENICITY OF ENGINEERED ANTIBODIES 348 16.1.5.2 ENGINEERING NEW
PROTEIN SCAFFOLDS 349 16.2 CONCLUSIONS 350
INDEX 357 |
| any_adam_object | 1 |
| author | Castanho, Miguel |
| author_GND | (DE-588)1011408384 |
| author_facet | Castanho, Miguel |
| author_role | aut |
| author_sort | Castanho, Miguel |
| author_variant | m c mc |
| building | Verbundindex |
| bvnumber | BV039109264 |
| classification_rvk | VS 5350 |
| classification_tum | CHE 820f CHE 893f |
| ctrlnum | (OCoLC)765929312 (DE-599)DNB1011200457 |
| dewey-full | 615.10724 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.10724 |
| dewey-search | 615.10724 |
| dewey-sort | 3615.10724 |
| dewey-tens | 610 - Medicine and health |
| discipline | Chemie / Pharmazie Chemie Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nam a2200000 c 4500</leader><controlfield tag="001">BV039109264</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20120726</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">110630s2011 ad|| |||| 00||| eng d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">11,N17</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">1011200457</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783527328918</subfield><subfield code="c">Gb. : ca. EUR 149.00 (DE) (freier Pr.)</subfield><subfield code="9">978-3-527-32891-8</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3527328912</subfield><subfield code="c">Gb. : ca. EUR 149.00 (DE) (freier Pr.)</subfield><subfield code="9">3-527-32891-2</subfield></datafield><datafield tag="024" ind1="3" ind2=" "><subfield code="a">9783527328918</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">Best.-Nr.: 1132891 000</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)765929312</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DNB1011200457</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-91G</subfield><subfield code="a">DE-526</subfield><subfield code="a">DE-355</subfield><subfield code="a">DE-19</subfield><subfield code="a">DE-M49</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615.10724</subfield><subfield code="2">22/ger</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">VS 5350</subfield><subfield code="0">(DE-625)147687:253</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">CHE 820f</subfield><subfield code="2">stub</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">CHE 893f</subfield><subfield code="2">stub</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">610</subfield><subfield code="2">sdnb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Castanho, Miguel</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)1011408384</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Peptide drug discovery and development</subfield><subfield code="b">translational research in academia and industry</subfield><subfield code="c">ed. by Miguel Castanho ...</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Weinheim</subfield><subfield code="b">Wiley-VCH</subfield><subfield code="c">2011</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XIX, 370 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield><subfield code="c">240 mm x 170 mm</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Wirkstofffreisetzung</subfield><subfield code="0">(DE-588)4190018-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Peptide</subfield><subfield code="0">(DE-588)4045125-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelforschung</subfield><subfield code="0">(DE-588)4003120-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Peptide</subfield><subfield code="0">(DE-588)4045125-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Wirkstofffreisetzung</subfield><subfield code="0">(DE-588)4190018-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Arzneimittelforschung</subfield><subfield code="0">(DE-588)4003120-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">X:MVB</subfield><subfield code="q">text/html</subfield><subfield code="u">http://deposit.dnb.de/cgi-bin/dokserv?id=3718083&prov=M&dok_var=1&dok_ext=htm</subfield><subfield code="3">Inhaltstext</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">DNB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=022653020&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-022653020</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV039109264 |
| illustrated | Illustrated |
| indexdate | 2024-07-20T11:12:41Z |
| institution | BVB |
| isbn | 9783527328918 3527328912 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-022653020 |
| oclc_num | 765929312 |
| open_access_boolean | |
| owner | DE-91G DE-BY-TUM DE-526 DE-355 DE-BY-UBR DE-19 DE-BY-UBM DE-M49 DE-BY-TUM |
| owner_facet | DE-91G DE-BY-TUM DE-526 DE-355 DE-BY-UBR DE-19 DE-BY-UBM DE-M49 DE-BY-TUM |
| physical | XIX, 370 S. Ill., graph. Darst. 240 mm x 170 mm |
| publishDate | 2011 |
| publishDateSearch | 2011 |
| publishDateSort | 2011 |
| publisher | Wiley-VCH |
| record_format | marc |
| spelling | Castanho, Miguel Verfasser (DE-588)1011408384 aut Peptide drug discovery and development translational research in academia and industry ed. by Miguel Castanho ... Weinheim Wiley-VCH 2011 XIX, 370 S. Ill., graph. Darst. 240 mm x 170 mm txt rdacontent n rdamedia nc rdacarrier Wirkstofffreisetzung (DE-588)4190018-2 gnd rswk-swf Peptide (DE-588)4045125-2 gnd rswk-swf Arzneimittelforschung (DE-588)4003120-2 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Peptide (DE-588)4045125-2 s Wirkstofffreisetzung (DE-588)4190018-2 s Arzneimittelforschung (DE-588)4003120-2 s DE-604 X:MVB text/html http://deposit.dnb.de/cgi-bin/dokserv?id=3718083&prov=M&dok_var=1&dok_ext=htm Inhaltstext DNB Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=022653020&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Castanho, Miguel Peptide drug discovery and development translational research in academia and industry Wirkstofffreisetzung (DE-588)4190018-2 gnd Peptide (DE-588)4045125-2 gnd Arzneimittelforschung (DE-588)4003120-2 gnd |
| subject_GND | (DE-588)4190018-2 (DE-588)4045125-2 (DE-588)4003120-2 (DE-588)4143413-4 |
| title | Peptide drug discovery and development translational research in academia and industry |
| title_auth | Peptide drug discovery and development translational research in academia and industry |
| title_exact_search | Peptide drug discovery and development translational research in academia and industry |
| title_full | Peptide drug discovery and development translational research in academia and industry ed. by Miguel Castanho ... |
| title_fullStr | Peptide drug discovery and development translational research in academia and industry ed. by Miguel Castanho ... |
| title_full_unstemmed | Peptide drug discovery and development translational research in academia and industry ed. by Miguel Castanho ... |
| title_short | Peptide drug discovery and development |
| title_sort | peptide drug discovery and development translational research in academia and industry |
| title_sub | translational research in academia and industry |
| topic | Wirkstofffreisetzung (DE-588)4190018-2 gnd Peptide (DE-588)4045125-2 gnd Arzneimittelforschung (DE-588)4003120-2 gnd |
| topic_facet | Wirkstofffreisetzung Peptide Arzneimittelforschung Aufsatzsammlung |
| url | http://deposit.dnb.de/cgi-bin/dokserv?id=3718083&prov=M&dok_var=1&dok_ext=htm http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=022653020&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT castanhomiguel peptidedrugdiscoveryanddevelopmenttranslationalresearchinacademiaandindustry |